A fluorescein-GLP-1 (7-37) analog was generated to determine GLP-1R distribution in various cell types of the pancreas in both strains of mice and receptor-specific uptake was confirmed by blocking with exendin-4. Biodistribution studies were carried out using 68 Galabeled GLP-1(7-37) peptides in CD1 and C57BL/6 mice. In addition, immunocompromised mice bearing GLP-1R-expressing insulinomas were evaluated by positron emission tomography (PET) imaging and ex vivo biodistribution studies. The optical GLP-1 probe strongly colocalized with immunofluorescence for insulin and glucagon, and more weakly with amylase (exocrine pancreas) and cytokeratin 19 (ductal cells), confirming its application for in situ GLP-1R imaging in various pancreatic cell types. Insulinomas were clearly visualized by in vivo PET. Reducing the peptide positive charge decreased renal retention as well as tumor uptake. Results demonstrate the application of the developed GLP-1 peptide analogues for in situ (optical) and in vivo (PET) imaging of GLP-1R expression.
O ne of the most significant advances in better understanding glucose regulation has been elucidating the incretin effect, referred to as the ability of orally administered nutrients or drugs to stimulate insulin secretion in a glucose-dependent manner. 1, 2 Glucagonlike peptide-1 (GLP-1), secreted from intestinal L cells following food ingestion, is a key incretin and has been shown to play a significant role in stimulating glucosedependent insulin secretion, inhibiting postprandial glucose release, delaying gastric emptying, and increasing satiety. [3] [4] [5] [6] Recent reports suggest the activation of GLP-1 receptors (GLP-1R) on pancreatic b cells to be a major variable in the action of GLP-1 on glucose metabolism. 7 Additionally, the GLP-1/GLP-1R interaction has been shown to decrease b cell apoptosis and increase differentiation of b cell precursor cells in the pancreas. 8 Therefore, the binding of GLP-1 to its receptor has direct implications for the treatment of type 2 diabetes mellitus, which is characterized by defects in pancreatic beta cell function and insulin sensitivity. 9 In addition to the important role of the GLP-1/GLP-1R axis in diabetes, GLP-1R activation by its recently developed ligands has been shown to control blood pressure, 10 reduce hepatic lipid accumulation, 11 prevent heart ischemia-reperfusion injury, 12 and rescue synaptic plasticity and memory deficits in mouse models of Alzheimer's disease. 13 The expression of GLP-1R has also been shown to be elevated in a number of cancers such as insulinomas, gastrinomas, and pheochromocytomas. 14 Among these, insulinomas express GLP-1Rs in high incidence (. 90%) and density (8133 dpm/mg tissue) more than any other peptide receptor in this tumor type. For the above reasons, GLP-1R is deemed a potential diagnostic target for imaging disease progression and therapeutic intervention. A class of tracers used for GLP-1R imaging is peptide-based compounds, with the first reported examples being 123 I-labeled GLP-1 and exendin-3 analogues. 15 However, the low peptide stability of GLP-1, as well as instability of radioiodine in vivo, limited the use and versatility of these tracers. More recently, radiolabeled exendin-4 (a GLP-1R agonist initially identified in extract from the saliva of Heloderma suspectum) analogues have shown promise in imaging of insulinomas in both animal models and human patients. [16] [17] [18] The most recent advances in this field, involving the use of 68 Ga, 64 Cu, 99m Tc, and 18 F-labeled exendin-4 analogues, have established GLP-1R as a suitable target for both positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] We have been interested in using the GLP-1 peptide, as the endogenous human GLP-1R ligand, in better understanding the GLP-1/GLP-1R interaction, and have accordingly reported the development of modified GLP-1 analogues with significantly enhanced serum protease stability (13 h for the modified peptide versus 15 min for native GLP-1). 29 In this study, we report the development of several stable, fluorescent, and 68 Ga-labeled GLP-1 analogues and their evaluation by optical imaging in vitro and PET imaging in vivo in insulinoma mouse xenografts. This report also presents an in vivo evaluation of several approaches in reducing renal and hepatic uptake of GLP-1 peptides, thereby providing an unbiased comparative study of the efficiency of such methods.
Materials and Methods
Common solvents and reagents were purchased from VWR (Missisauga, ON), Fisher Scientific (Ottawa, ON), or Sigma-Aldrich (Oakville, ON) and used as received, unless stated otherwise. Sterile, deionized water was used in all aqueous procedures. All fluorenylmethyl carbamate (Fmoc)-protected amino acids, except Fmoc-lysine [Lys] (4-methyltrityl [mtt])-OH (Nova Biochem, Etobicoke, ON) and N,N,N9,N9-tetramethyl-O-(1H-benzotriazol-1yl)uronium hexafluorophosphate (HBTU), were obtained from Peptides International (Louisville, KY). Fmoc-Rink amide 4-methylbenzhydrylamine (MBHA) resin (4-(29, 49dimethoxyphenyl-(9-fluorenylmethoxycarbonyl)-aminomethyl)phenoxy-acetamido-norleucyl-4-methyl benzhydrylamine resin) and Boc-His(Boc)-OH-dicyclohexylamine (DCHA) were obtained from Nova Biochem. The hydrophilic linker 2-(2-[2-aminoethoxy]ethoxy) acetic acid (AEEA) was synthesized according to literature reports. 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)tris(tert-butoxy [tBu])-ester was obtained from CheMatech (Dijon, France). Chinese hamster ovary cells stably transfected with the human GLP-1 receptor (CHO/GLP-1R) and INS-1 832/13 cells were provided by Dr. Michael Wheeler from University of Toronto and Dr. Christopher Newgard from Duke University, respectively. Gallium-68 generator and all automated synthesis modules were purchased from Eckert and Ziegler (Valencia, CA).
Peptide Synthesis
Fmoc-based solid phase peptide synthesis was carried out using an APEX 396 autosynthesizer (Louisville, KY) (AAPPTEC) with 0.05 meq of 0.27 mmol/g Fmoc-Rink amide MBHA resin and a three fold excess of the protected amino acids. Fmoc removal, carried out with 20% piperidine in DMF (N,N-dimethylformamide) over two cycles (10 and 20 min), was followed by amino acid activation with 3 eq HBTU and 6 eq N,N-diisopropylethylamine (DIPEA) (10 min) and subsequent coupling over 30 and 120 minute cycles. Methyl trityl deprotection was carried out in a glass peptide reaction vessel using 5% triisopropylsilane (volume/volume [v/v]) + 2% trifluoroacetic acid (TFA) (v/v) in dichloromethane (CH 2 Cl 2 ) over 3 minutes and repeated 10 times. Coupling of DOTA/AEEA to this site, or the coupling of DOTA to AEEA, followed the same methodology used in amino acid coupling; however, the coupling times were increased to 18 and 24 hours for AEEA and DOTA, respectively. For the preparation of fluorescent GLP-1 analogues, conjugation of fluorescein isothiocyanate (FITC) to mtt-deprotected Lys37 was carried out using a four fold excess of FITC and DIPEA in DMF. This conjugation reaction was monitored using the Kaiser test and was completed in 23 hours. Microcleaved samples were also used to monitor reaction progress and peptide purity via high performance liquid chromatography (HPLC). Full deprotection of synthesized peptides was accomplished using a solution of 88% TFA (v/v) + 5% water (v/v) + 5% phenol (mass/volume [m/v]) + 2% triisopropylsilane (v/v) over 6 hours. The cleaved peptides were then precipitated using tert-butyl methyl ether (TBME) and centrifuged (2200 rpm for 15 min). After removing the resulting supernatant, the peptide pellet was rinsed with TBME, vortexed, and centrifuged again (2200 rpm for 15 min). The supernatant was removed and the peptide pellet was dissolved in water, frozen at 278 o C and lyophilized.
Synthesis of Modified GLP-1 Analogue
GLP-1 derivatives were prepared using Fmoc solid phase methodology as previously reported. 29 Glycine37 was replaced with Fmoc-Lys(allyloxycarbonyl [Alloc])-OH, while Fmoc-Lys(mtt)-OH residues used in positions 26 and 34 were acylated. In a typical experiment, 0.05 meq of peptide-loaded resin was swollen in DMF. Methyl trityl deprotection of Lys26 and Lys34 side chains was carried out in a glass peptide reaction vessel using 5% triisopropylsilane (v/v) + 2% TFA (v/v) in CH 2 Cl 2 over 3 minutes (repeated 310). The resin was washed thoroughly with DMF and dichloromethane, respectively. A 7 mL solution of 10% acetic acid anhydride in DMF was then added to the resin followed by shaking over 15 minutes (repeated 3 5). Completion of acylation reactions (ie, presence of free amines) were monitored by Kaiser tests. DOTA coupling then proceeded as stated previously.
Purification and Characterization
Peptides were analyzed using a reverse phase (RP) analytical HPLC column (Grace Vydac Protein/Peptide RP-C18 column, 4.6 3 250 mm, 5 mm, Calgary AB). This system was equipped with a Waters 600 controller, Waters Prep degasser, and Waters MassLynx software, version 4.1 (Mississauga, ON). Employed mobile phases were 0.1% TFA in water (eluent A) and 0.1% TFA in acetonitrile (CH 3 CN) (eluent B). The linear gradient used was 30 to 50% of B with a flow rate of 1.5 mL/min over 20 minutes. The column eluate was monitored using a Waters 2998 photodiode array detector set at 220 and 254 nm. Peptides were purified using an RP preparative HPLC column (Grace Vydac Protein/Peptide RP-C18 column, 22.0 3 250 mm, 10 mm) on the same system mentioned above. The detection method along with eluents and gradients were the same as those stated above, with the exception of the flow rate being set at 20 mL/min. The collected fraction was then lyophilized to a solid and subsequently analyzed by electrospray ionization mass spectrometry (ESI-MS) (Waters Micromass Quattro Micro API). Purity of final products was determined by analytical RP-HPLC. Selected data are shown in Figures S1-S5.
69/71 Ga Coordination
In a typical reaction, 10 mg of GLP-1 analogue was dissolved in pH 4 sodium acetate/acetic acid (NaOAc/ HOAc) buffer. Chelation was carried out using a two fold excess of anhydrous gallium trichloride (GaCl 3 ) at 75 o C over 30 minutes. The resulting mixture was cooled prior to purification by a plus C18 RP Sep-Pak (Waters, Mississauga, ON) (conditioned with 6 mL of ethanol [EtOH] and 25 mL of water). After passing the reaction mixture through the Sep-Pak, 10 mL of water was used as eluent in order to wash out residual unreacted GaCl 3 . A 6 mL aliquot of EtOH was used to wash out the labeled product. The resulting solution was then dried on a rotary evaporator, mixed with 10 mL of water, frozen at 278 o C, and subsequently lyophilized overnight.
Binding Assays
All GLP-1 receptor binding studies were conducted using CHO/GLP-1R, generously donated by Dr. Michael Wheeler, University of Toronto. Receptor binding was measured by the displacement of [ 125 I]-exendin-4 with increasing concentrations of the synthesized GLP-1 analogues, using a previously published method. 29 Briefly, CHO/GLP-1R cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Invitrogen, Burlington, ON) containing 10% fetal bovine serum (Invitrogen). On the day of the experiment, cells were rinsed 23 with warm Hank's buffered saline solution (HBSS) and dissociated in HBSS containing 2 mM EDTA. Approximately one million cells were incubated for 60 minutes at 37 o C in binding buffer (DMEM containing 0.1% aprotinin (Bayer, Leverkusen, Germany) and 0.1% bovine serum albumin (Sigma) (pH 7.4), 0.77 mmol [ 125 I]exendin-4 (Amersham, Piscataway, NJ), and variable concentrations of each GLP-1 analogue (10 -5 to 10 -11 M). After incubation, cells were centrifuged at 2800 rpm for 15 minutes. After removal of the supernatants, the cell pellets were washed with 200 mL of cold binding buffer and recentrifuged before the final pellet was counted in a gamma counter. Binding curves and half maximal inhibitory concentration (IC 50 ) values were generated using MS Excel and GraphPad Prism 6.
Cyclic Adenosine Monophosphate Radioimmunoassay
Activation of the GLP-1 receptor by the peptide analogues was assessed by stimulation of cyclic adenosine monophosphate (cAMP) using a previously published method. 29 Briefly, CHO/GLP-1R cells were plated at a density of 1310 5 cells/well in a 24-well plate 48 hours prior to the day of the experiment. Cells were incubated for 30 minutes at 37 o C in DMEM containing 0.4% glucose, 1% bovine serum albumin and 1 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma) (pH 7.4) and varying concentrations (10 26 to 10 210 M) of the peptide analogues. Media were removed; cells were rinsed twice with cold HBSS and scraped in 200 mL of 80% EtOH in HBSS on ice. cAMP levels were measured using a cAMP radioimmunoassay kit (Perkin Elmer, Shelton, CT) as per the manufacturer's instructions. One-way analysis of variance (ANOVA) was conducted to determine significant differences in half maximal effective concentration (EC 50 ) values followed by Tukey's posthoc test. Significance was set at p , .05 for all analyses.
Fluorescence Immunohistochemistry
All mice were treated in accordance with the guidelines set out by the Animal Use Subcommittee of the Canadian
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Council on Animal Care at The University of Western Ontario. After sacrifice, pancreata from adult (8 to 12 weeks of age) male or female CD1 and C57BL/6 mice were excised, fixed in 10% neutral buffered formalin for 24 to 36 hours, and embedded in paraffin. Serial sections were cut at 5 mm, and five sections per animal were selected for immunohistochemistry. One section was incubated with 0.5 mM (Dalanine [Ala]8, Lys[fluorescein]37)GLP-1(7-37) amide for 5 minutes, then washed 3 3 5 minutes with PBS. Adjacent sections were prepared for immunohistochemistry as described previously using the following primary antibodies: anti-insulin (1:1000, Sigma) to visualize islets and beta cells; anti-glucagon (1:200, Sigma) to visualize alpha cells; anti-cytokeratin (CK) 19 (1:100, Santa Cruz Biotech, Dallas, TX) to visualize ductal cells; and anti-amylase (1:50, Santa Cruz Biotech) to visualize exocrine cells. 30 Images were captured with an Olympus I wide-field fluorescence microscope (original magnification 381). Image acquisition was carried out using In Vivo software. Ten optical sections per cell were collected in 0.2 mm steps covering the z-axis field, using a 603 oil immersion objective lens. Cell images were processed using a three-dimensional blind deconvolution algorithm provided in Image Pro Plus software.
Ga Labeling
To a clean glass microwave vessel, 100 mL of GLP-1 analogue solution (1 mg/mL in pH 3.5 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES] buffer) was added. This aliquot was dissolved in 900 mL of the buffer (10-fold dilution to obtain solutions with mM final concentrations), to which 3 mCi 68 GaCl 3 was added, freshly eluted from an Eckert and Ziegler germanium-68 ( 68 Ge)/ 68 Ga generator using 3 mL of 0.1 M hydrochloric acid (HCl). Purification and isolation of 68 Ga was achieved using a Phenomenix Strata-X-C 33u polymeric strong cation exchange column (Torrance, CA) (30 mg/mL) with 0.05 N HCl in acetone as the eluent. The reaction mixture was then heated in the reactor of the automated synthesis module at 80 o C for 30 minutes, prior to Sep-Pak purification using a light RP-tC18 SPE Sep-Pak cartridge (conditioned with 3 mL of EtOH and 10 mL of water). After passing the reaction mixture through the Sep-Pak, 3 mL of water was used as eluent in order to wash out residual unreacted 68 Ga materials. A 2 mL aliquot of EtOH was used to wash out the radiolabeled product. After evaporation of the solvent on a V-10 1.6 Biotage vortex and vacuum evaporation system (Charlotte, NC), the reaction progress and product purity were analyzed using analytical RP-HPLC (Sunfire RP-C18 column, 4.6 3 150 mm, 5 mm, Mississauga, ON) coupled to a gamma detector, prior to further use in animal studies. HPLC system employed a Waters 1525 binary HPLC pump, Waters 2487 dual l absorbance detector, Waters in-line degasser, and Breeze software (version 3.30).
In Vivo PET Imaging
All mice were treated in accordance with the guidelines set out by the Animal Use Subcommittee of the Canadian Council on Animal Care at The University of Western Ontario. For imaging studies of insulinomas, male Balb/c nu/nu mice (8 to 12 weeks of age) were injected subcutaneously in the left flank with 2 3 10 6 INS-1 832/13 cells. Tumors were allowed to develop for 14 to 21 days (to a 4 to 5 mm diameter). On the day of imaging, mice were anesthetized with 3% isoflurane and intubated with a mixture of air and 1.5% isoflurane. Each mouse was injected via tail vein catheter with 10 MBq of the 68 Ga-GLP-1 derivative and immediately placed on the scanner bed of a General Electric Healthcare Explore Vista DR PET scanner (Mississauga, ON). Static scans were acquired 90 minutes postinjection (p.i.). Image acquisition, correction, and reconstruction were conducted as described previously. 30 After the imaging session, mice were sacrificed by cervical dislocation; the tumor and other tissues were immediately removed, weighed, and counted for biodistribution, as described below.
Biodistribution
Adult male CD1 and C57BL/6 mice were anesthetized under 2% isoflurane during tail vein catheter insertion, injection, and during cervical dislocation. CD1 mice (20 to 28 g, 6 to 8 weeks of age) were administered 3 MBq of 68 Ga-GLP-1 peptide. Similarly, C57BL/6 mice (17 to 23 g, 6 to 8 weeks of age) were injected with 3 MBq of the 68 Ga-GLP-1 analogue alone or coinjected with 1 mM unlabeled exendin-4 for blocking studies. Mice were sacrificed at 3 minutes, 30 minutes, 1 hour, and 4 hours p.i. The pancreas and other organs of interest were excised, washed in cold PBS, weighed, and counted in a high purity Ge gamma counter. Probe uptake was expressed as percent injected dose per gram (%ID/g) tissue, and all activity was decay-corrected to the time of injection. Statistical differences between time points and mouse strains were determined with two-way ANOVA and posthoc independent sample t-tests using SPSS v17.0, and significance was set at p , .05.
Results

Synthesis of GLP-1 Analogues
GLP-1 analogues were synthesized using standard Fmoc-SPPS chemistry with an automated multi-well synthesizer. Figure 1 illustrates the synthetic approach used for the preparation of the GLP-1 analogues in this study. An orthogonal protecting group strategy was employed for site-specific modification of the peptide backbone. Amino acids with reactive side chains were protected with tertbutyl ester (OtBu), tert-butyl (tBu), triphenylmethyl (Trt), and pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl (Pbf) while the site of modification, the e-amine of a Lys side chain positioned at Lys37, was protected with the temporary protecting group mtt. All other Lys residues in the peptide main chain were protected with Boc groups, which are much less acid labile. Inert and thermodynamically stable metal chelators are commonly used in conjugation of radiometals to peptides. In this study, the commonly used and versatile macrocycle DOTA was employed in the development of modified GLP-1 peptide PET tracers. DOTA was replaced with a dye (FITC) for in vitro optical evaluation of GLP-1R expression in various pancreatic cell types. To reduce steric effects imposed by GLP-1 Peptide Analogues for GLP-1R Imaging the metal chelator DOTA on the binding site of the peptide derivatives, a short polyethyleneglycol chain, 2-[2-(2aminoethyl)ethoxy]acetic acid (AEEA), was employed as a spacer to separate the metal chelator complex from the main peptide chain. The AEEA spacer was synthesized according to published procedures. 31 Peptide samples were taken at various intervals and, following full deprotection, were analyzed using ESI-MS and RP-HPLC. Typical overall reaction yields for the purified DOTA and fluorescein-conjugated GLP-1 analogues were 10 to 15% with purities . 98%.
69/71 Ga Chelation
Initial labeling experiments were carried out using naturally occurring 69/71 Ga (Figure 2 ), in order to obtain HPLC standards and determine radiolabeling conditions while preventing unnecessary exposure to radiation. Reaction solvent and temperature were optimized for complete labeling on peptides. Products were purified using preparative HPLC and characterized using ESI-MS prior to biological evaluation.
In Vitro Assays
The purified GLP-1 analogues were evaluated using competitive receptor binding assays where the displacement of [ 125 I]exendin-4 by the peptide on CHO/GLP-1R cells was used as a measure of the respective IC 50 values (Table 1, Figure 3 ). Results suggest that acylation of the peptide backbone had minimal impact on the binding affinity of the nonacylated GLP-1 analogue (1) (IC 50 14.9 nM vs 23.4 nM for Acyl-1) and 3 (IC 50 38.6 nM vs 24.6 nM for Acyl-3). The ability of the modified GLP-1 peptides to activate GLP-1 receptors was assessed by measuring cAMP levels in response to various concentrations of peptide as reported previously. 29 All GLP-1 analogues significantly increased cytoplasmic cAMP concentrations (see Table 1 , Figure 3 analogues still act as GLP-1R agonists. However, acylation appeared to reduce the extent of GLP-1R signaling.
Radiolabeling of GLP-1 Analogues with 68 Ga
In a typical experiment, 68 Ga was eluted from the generator using 3 mL of 0.1 N HCl, and loaded onto a Phenomenix Strata-X-C 33u polymeric strong cation exchange column for purification. 68 Ga was then eluted from the cation exchange cartridge using 0.4 mL of 0.05 N HCl in 98% acetone, and carried to the reaction vessel. After completion of the reaction, carried out at 80 o C over 30 minutes, the radiolabeled product was purified by RP-C18 Sep-Pak and dried on a Biotage rapid solvent evaporator system. The choice of solvent and quantities of GLP-1 analogues were optimized in order to maximize radiochemical yields. Radiochemical yields increased with increasing starting peptide amounts. Considering that the use of larger peptide quantities results in lower specific activities, the maximum quantity of peptide used was set at 100 mg, resulting in an 85 to 90% decay-corrected radiochemical yield and . 98% radiochemical purity. Ideal radiolabeling conditions were found to be in a pH 3.5 HEPES buffer using 100 mg of the GLP-1 peptide derivative. Figure 2 illustrates typical radio and ultraviolet chromatograms from this reaction.
Fluorescence Immunohistochemistry
Retrieved adult male CD1 and C57BL/6 mice pancreas were prepared for immunohistochemistry using antiinsulin, anti-CK19, anti-glucagon, and anti-amylose antibodies in order to visualize various pancreatic cell types using the developed optical GLP-1 analogue, 2. Fluorescence images from the pancreata of both CD1 and C57BL/6 mice clearly demonstrated localization of 2 in beta and alpha cells, and to a somewhat lesser extent in acinar and ductal cells (Figure 4 ). Blocking of 2 with excess unlabeled exendin-4 in tissues from both strains of mice resulted in a significant reduction in fluorescence intensity in islets and surrounding exocrine tissue ( Figure 5 ).
In Vivo Imaging of GLP-1R Expression and Biodistribution of 68 Ga-GLP-1 Analogues
For biodistribution studies in normal CD1 and C57BL/6 mice, 3 MBq of the 68 Ga-GLP-1 analogue was administered, and mice were sacrificed 3 minutes, 30 minutes, 1 hour, and 4 hours p.i. Pancreatic uptake (in CD1/C57BL/6 mice) was 0.26%/0.26% at 3 minutes, 0.09%/0.15% at 30 minutes, 0.06%0.05% at 1 hour, and 0.07%/0.02% at 4 hours p.i. In Balb/c nu/nu mice harboring insulinomas, tumors were clearly visualized 90 minutes p.i. of 10 MBq of either 1 or the Acyl-1 analogue ( Figure 6 ). Acylation reduced kidney retention from 49.2 to 33.4%, but also resulted in a lower tumor uptake (3.41% for 1 vs 1.08% for Acyl-1).
Discussion
We previously developed a modified GLP-1 peptide analogue with significantly enhanced serum protease GLP-1 Peptide Analogues for GLP-1R Imaging stability (13 h), compared to native GLP-1 (15 min), and confirmed its potential for SPECT imaging with a preliminary in vitro analysis of the 111 In-labeled peptide. 29 The objective of the current study was to evaluate the potential of this peptide as a GLP-1R imaging agent in vitro (optical) and in vivo (PET) in insulinoma-bearing mouse xenografts. As in our last report, enhanced protease stability was achieved by substitution of L-Ala at position 8 with D-Ala, leading to improved resistance to degradation by dipeptidyl peptidase-4 (DPP-IV). Derivatives without (1) and with (3) a linker between the peptide and the radiometal complex were prepared. Consistent with our last report of modified GLP-1 analogues, 1 exhibited a higher binding affinity and was therefore selected for subsequent in vivo analysis. The lower binding affinity of 3 may have been a result of destabilization of its helical conformation via steric hindrance or strain caused by the AEEA chain. 32 The fluorescein-GLP-1 peptide (2) exhibited a receptor binding affinity similar to the previously reported analogue, indicating that the optical tag did not interfere with receptor binding. Measurement of intracellular cAMP levels indicated all developed peptide analogues to be GLP-1R agonists. The expression and distribution of GLP-1R in all pancreatic cell types were studied in situ in CD1 and C57BL/6 mice. Figure 4A illustrates colocalization of 2 signal with immunofluorescent staining of insulin (beta cells), glucagon (alpha cells), amylase (acinar cells), and CK19 (ductal cells) in CD1 mice. As expected, strong colocalization of 2 with insulin-positive cells was observed; however, there was also strong fluorescent signal that colocalized with glucagon-positive cells (arrows). Weaker fluorescence signals showed colocalization with amylase and CK19 immunofluorescence. In contrast, in C57BL/6 mice, there was equally strong fluorescence in insulin-and glucagon-positive cells in the islet (see Figure 4B ) and much weaker fluorescent signal in amylase-and CK19positive cells. Our report is consistent with evidence of GLP-1R expression in ductal cells, as demonstrated by immunofluorescence microscopy and GLP-1R signaling in acinar cells. 33, 34 Interestingly, there is some controversy as to whether pancreatic alpha cells express GLP-1R, considering that there is neither a secretory response to GLP-1 nor evidence of GLP-1R mRNA in isolated rat pancreatic alpha cells. Literature reports suggest a fraction of alpha cells express GLP-1R during embryonic development in mice. 35 Our results suggest the presence of GLP-1R on some alpha cells may persist in adult mice. More extensive analysis of islet sections from several strains of mice, as well as human islets, with this fluorescein-GLP-1 analogue will more definitively determine if GLP-1R is expressed in normal alpha cells. Specific binding of the peptide to islet GLP-1R was confirmed by blocking with 1 mM exendin-4 in islets from both CD1 and C57BL/6 mice pancreata (see Figure 5 ). The above results demonstrate the application of 2 for in situ visualization of GLP-1R expression on various cell types of the pancreas.
A major limitation of peptide-based tracers is enhanced renal retention, primarily attributed to the presence of positive charged amino acids such as Lys and arginine (Arg). 36, 37 As a result, various studies have focused on neutralization of overall charges in an effort to lower tracer isoelectric points and kidney residence times. Examples of these studies include the use of 2,3,5,6-tetrafluorophenyl glycolate or acylation to neutralize positive charges in anti-Tac disulfide-bonded variable region side-chain Fv fragments, which lowered renal retention while maintaining GLP-1 Peptide Analogues for GLP-1R Imaging tumor uptake. [38] [39] [40] Renal retention of Indium-111 diethylenetriaminepentaacetic acid ( 111 In-DTPA)-conjugated peptides, such as octreotide, was reduced by increasing the overall negative charge on the peptide backbone by substitution of phenylalanine by aspartic acid. 41, 42 We speculated that acylation of Lys residues, as well as substitution of Arg residues with Gly, may aid in reducing positive charges in the GLP-1 peptide backbone, while maintaining sufficient receptor affinity. The selection of residues for acylation and substitution took charge and essential residues for binding (ie, His7, Gly10, Phe12, Tyr13, Asp15, Phe28, Ile29, and Val22) into consideration. As such, Gly37 was replaced with Lys37 (later used for DOTA conjugation), while Lys34 and Lys26 were acylated. In addition, Arg36 was replaced with Gly to further reduce the overall peptide positive charge, a decision made based on reported Ala scans confirming that the guanidinium moiety is not essential in the receptor-ligand interaction.
Following synthesis, purification, and characterization of all peptides, in vitro binding studies indicated similar GLP-1 receptor affinity for all developed peptides (see Table 1 , Figure 3 ), thereby confirming minimal impact of acylation on ligand-receptor interactions. In addition, all analogues significantly increased cytoplasmic cAMP concentrations, implying an agonistic interaction with GLP-1R. However, compared to 1, the acylated peptide (Acyl-1) demonstrated less agonistic activity.
The potential of the acylated (Acyl-1) and nonacylated GLP-1 (1) analogues for GLP-1R visualization was evaluated in xenografted insulinoma mouse models. Following administration of the 68 Ga-GLP-1 analogues, insulinoma tumors were successfully visualized 90 minutes p.i. via PET (see Figure 6 ), thereby confirming the potential of these tracers for in vivo imaging of GLP-1R overexpression. While acylation reduced tracer kidney retention (49.2 %ID/g for nonacylated GLP-1 versus 33.4 %ID/g for acylated GLP-1), it also lowered uptake by insulinoma cells (3.41 %ID/g for the nonacylated versus 1.08 %ID/g for the acylated GLP-1). This could have resulted from enhanced peptide lipophilicity or steric hindrance imposed by acylated sites on receptor-ligand interactions. GLP-1 tracers, while allowing for visualization of insulinomas, exhibited lower overall retention in insulinoma xenografted mice when compared to reported exendin-3 and 4 analogues. For instance, kidney retention, the organ exhibiting the highest accumulation of any reported analogue, of 68 Ga-GLP-1 (1) was 49.2% compared to . 75% for 111 In-exendin-9 and . 170% for 111 Inexendin-3 and 111 In-exendin-4 analogues. This implies a much faster overall clearance rate for GLP-1 analogues.
Targeted tumor uptake of 68 Ga-GLP-1 (1) was higher (3.4%) than radiolabeled Exendin-9 (0.8%) analogues while being lower than exendin-3 and 4 derivatives (. 25%). 17 These results further demonstrate the utility of targeting GLP-1R for imaging of insulinomas while bringing insight into individual abilities of the various classes of GLP-1R targeted tracers. In addition, there is also some evidence that GLP-1R is overexpressed in benign, but not malignant, insulinomas, thus demonstrating that a targeted approach to imaging GLP-1R may distinguish different forms of disease. 43 We also attempted to visualize pancreatic GLP-1R expression in nonxenografted CD1 and C57BL/6 mice using 68 Ga-GLP-1 (1) . Although biodistribution studies in both CD1 and C57BL/6 mice confirmed early pancreatic uptake with subsequent clearance over 4 hours p.i., we were unable to delineate the pancreas in PET images due to accumulation of the signal in the kidneys (data not shown). Our attempts to reduce tracer retention in kidneys by using acylated 68 Ga-GLP-1 were unsuccessful in definitively visualizing pancreatic GLP-1R expression. These results are consistent with previous attempts at visualization of endogenous, intact islets by targeting GLP-1R in rodents. 44, 45 More recently, however, intact islets in a primate model were successfully imaged, 46 thus demonstrating the potential of GLP-1R targeting in larger animals.
Conclusions
Modified GLP-1 analogues were synthesized and evaluated in vitro and in vivo for optical and PET imaging of GLP-1 receptor expression. Metal chelation conditions for the naturally occurring nonradioactive 69/71 Ga as well as radioactive 68 Ga were optimized. The optical analogue 2 is a suitable candidate for ex vivo visualization of GLP-1R expression on various pancreatic cell types, especially glucagon-positive cells. 68 Ga-1 is a promising candidate for in vivo PET imaging of GLP-1R in insulinoma mouse xenografts. Acylation of the peptide backbone proved to be beneficial in improving renal clearance of 2; however, this also resulted in a lower tumor uptake.
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